Howard Liebman, MD

Professor of Medicine and Pathology

Donald I. Feinstein, MD, Chair in Hematology

Is this your profile? Click to edit

Overview

Dr. Howard Liebman, Professor of Medicine and Pathology is the author or co-author of over 170 peer reviewed publications, review articles and chapters. He has presented over two hundred lectures across the United States, South America, Europe. Korea and Japan. He has served as the former Chair of the Massachusetts Governor’s Task Force subcommittee on experimental therapies and clinical trials for AIDS. He is a medical advisor for the Platelet Disorder Support Association and a member of the Cancer and Thrombosis Guidelines Committee of the American Society of Clinical Oncology. He has served on several grant review committees for the National Institute of Health. He presently holds the Donald I Feinstein Endowed Chair of Hematology.

In addition to his academic responsibilities, Dr. Liebman is an attending staff member of the LAC+USC Medical Center, the USC/Norris Comprehensive Cancer Center and the Keck Hospital of USC. Dr. Liebman also is on the forefront of research in thrombotic and hemorrhagic disorders. His lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, and arterial thrombosis. Dr. Liebman is also internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy. He has been and is the principal investigator on several clinical trials in the management of immune thrombocytopenia (ITP). His research group has made important discoveries on the role of infectious agents in the development of immune thrombocytopenia and secondary ITP.

Awards

American College of Physicians: Fellow

Education and Training

Keck School of Medicine — MD — Medical School, Doctor of Medicine
LAC + USC Medical Center — Internship, Internal Medicine
LAC + USC Medical Center — Residency, Internal Medicine
LAC + USC Medical Center — Fellowship, Hematology
Tufts-New England Medical Center — Fellowship in Immunochemistry and coagulation chemistry

Research Funding

ROLE OF METAL IONS IN THE FUNCTION OF HUMAN FACTOR IX
NIH · R29HL039665 · Feb 15, 1988 – Mar 1, 1994 · Role: Principal Investigator

Publications

Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003; 111(4-5):235-8.. View in PubMed
Anticoagulation is an effective treatment for aortic mural thrombi. J Vasc Surg. 2002 Oct; 36(4):713-9.. View in PubMed
Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002 Oct; 61(10):922-4.. View in PubMed
Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002 Sep; 118(4):1166-9.. View in PubMed
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002 Aug; 88(2):213-20.. View in PubMed
Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol. 2001 Nov; 68(3):202-9.. View in PubMed
Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency. Cancer. 2001 Feb 15; 91(4):636-41.. View in PubMed
Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume. Skeletal Radiol. 2000 Oct; 29(10):563-71.. View in PubMed
Ticlopidine-induced aplastic anemia: development of chromosomal abnormalities and response to immunosuppressive therapy. Am J Hematol. 2000 Mar; 63(3):141-4.. View in PubMed
Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol. 2000 Mar; 63(3):109-13.. View in PubMed